Reviva reports Q3 loss of $10.5M; Phase 3 brilaroxazine trial meets all endpoints

REVIVA PHARMACEUTICALS HOLDINGS, INC.

Phase 3 RECOVER trial met primary endpoint: 10.1-point PANSS reduction for 50 mg brilaroxazine vs placebo at week 4 (p<0.001).
Net loss for Q3 2023 of $10.5M ($0.44/share) vs $3.5M loss ($0.18/share) in Q3 2022.
Cash of $5.0M as of Sep 30, 2023, down from $18.5M at Dec 31, 2022.
Anticipated milestones: OLE data Q4 2024; RECOVER-2 initiation Q1 2024; NDA submission 2025.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

REVIVA PHARMACEUTICALS HOLDINGS, INC. reported third quarter ended September 30, 2023 results: net income approximately $10.5 million, EPS ($0.44) per share.

Period: third quarter ended September 30, 2023
Net income: approximately $10.5 million
EPS: ($0.44) per share
Result: reported results

Exact text from the filing

The Company reported a net loss of approximately $10.5 million, or ($0.44) per share, for the three months ended September 30, 2023

View on SEC.gov

20 earnings releases filed in the last 30 days. Browse all earnings releases →

REVIVA PHARMACEUTICALS HOLDINGS, INC. filing history →

Source: SEC EDGAR

accession 0001437749-23-031971

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.